glp 1 stimulation GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development GLP1-GIP receptor co-agonists: a promising

Unknown Pharmacokinetics We dont fully understand how these medications behave in the body at micro-doses, including their absorption, distribution, and elimination patterns

Ding, F., Wang, Q., Xie, C., Wang, M., Zhang, L., Gao, M., Yang, Z., Ma, J., Shi, X., Chen, W., Duan, S., Yuan, P., Li, Y., Ma, X., Wu, Y., Liu, J., Feng, X., Cheng, Q., Wang, Z., Li, X., Huang, J

Marzo, A., Arrigoni Martelli, E., Mancinelli, A., Cardace, G., Corbelletta, C., Bassani, E

1 Close monitoring and careful dose adjustments, especially when initiating therapy, are recommended for patients with gastroparesis or severe gastroesophageal reflux disorder (GERD) due to the ability of GLP-1 RAs to slow gastric emptying